The Effects of Nano-Curcumin Supplementation on Risk Factors for Cardiovascular Disease: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials
Damoon Ashtary-Larky,
Mahnaz Rezaei Kelishadi,
Reza Bagheri,
Seyedeh Parisa Moosavian,
Alexei Wong,
Sayed Hossein Davoodi,
Pardis Khalili,
Frédéric Dutheil,
Katsuhiko Suzuki,
Omid Asbaghi
Affiliations
Damoon Ashtary-Larky
Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 6135715794, Iran
Mahnaz Rezaei Kelishadi
Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran
Reza Bagheri
Department of Exercise Physiology, University of Isfahan, Isfahan 8174673441, Iran
Seyedeh Parisa Moosavian
Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran
Alexei Wong
Department of Health and Human Performance, Marymount University, Arlington, VA 22207, USA
Sayed Hossein Davoodi
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran 1416753955, Iran
Pardis Khalili
Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran 1416753955, Iran
Frédéric Dutheil
CNRS, LaPSCo, Physiological and Psychosocial Stress, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Preventive and Occupational Medicine, WittyFit, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
Katsuhiko Suzuki
Faculty of Sport Sciences, Waseda University, 2-579-15 Mikajima, Tokorozawa 359-1192, Japan
Omid Asbaghi
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran 1416753955, Iran
Previous studies have indicated that curcumin supplementation may be beneficial for cardiometabolic health; however, current evidence regarding the effects of its nanorange formulations, popularly known as “nano-curcumin”, remains unclear. This systematic review and meta-analysis aimed to determine the impact of nano-curcumin supplementation on risk factors for cardiovascular disease. PubMed, Scopus, Embase, and ISI web of science were systematically searched up to May 2021 using relevant keywords. All randomized controlled trials (RCTs) investigating the effects of nano-curcumin supplementation on cardiovascular disease risk factors were included. Meta-analysis was performed using random-effects models, and subgroup analysis was performed to explore variations by dose and baseline risk profiles. According to the results of this study, nano-curcumin supplementation was associated with improvements in the glycemic profile by decreasing fasting blood glucose (FBG) (WMD: −18.14 mg/dL; 95% CI: −29.31 to −6.97; p = 0.001), insulin (WMD: −1.21 mg/dL; 95% CI: −1.43 to −1.00; p p p p = 0.003) and interleukin-6 (IL-6) (WMD: −2.78 mg/dL; 95% CI: −3.76 to −1.79; p < 0.001). Moreover, our results showed the hypotensive effect of nano-curcumin, evidenced by a decrease in systolic blood pressure (SBP). In conclusion, our meta-analysis suggests that nano-curcumin supplementation may decline cardiovascular disease risk by improving glycemic and lipid profiles, inflammation, and SBP. Future large-scale investigations with longer durations are needed to expand on our findings.
